

San Francisco Bay Area

Market overview

The San Francisco Bay Area continues to be a hot spot for the life science sector. Because of the current pandemic, the Bay Area's biotech industry is booming as many companies continue their pursuit for more research on combating COVID-19 and other infectious diseases.



Overall
Vacancy
5.6%



Delivering
by year end
0.8 msf



Overall avg.
asking rate
\$3.72



Total building
inventory
25.6 msf


East Bay Benefits

Stockbridge is yet another owner to have transitioned over to the East Bay. They've recently acquired more biotech property within Alameda, including the Waterfront at Harbor Bay campus, citing that it is the perfect location for life science tenants who would like to stay within the cluster of the Bay Area, without being directly overshadowed by some of the largest pharmaceutical giants located across the Bay.



San Francisco
Bay Area Ranked
#2
in nation
(according to Sum Of NIH
Funding Recipients)

Life science deliveries vs vacancy rate



Notable transactions (year-to-date)

Tenant/Buyer	Address	Submarket	Type	SF
Ventas	Genesis Tower/4000 Shoreline	South San Francisco	Sale	793,000
Stockbridge Capital Group LLC	Portfolio	Alameda	Sale	606,677
Guardant Health	3000 Hanover St	Palo Alto	Lease	249,549
Boston Properties	701 Gateway Blvd	South San Francisco	Sale	170,862
Kodiak Sciences	1050 Page Mill Rd	Palo Alto	Lease	155,466
Sutro Biopharma	111 Oyster Point Blvd	South San Francisco	Lease	115,466

Notable life science developments


Project	Developer	Submarket	SF	Completion	Preleased
Gateway of Pacific Phase II-III	BioMed Realty	South San Francisco	790,000	Q3 2021	30%
Kilroy Oyster Point Phase I	Kilroy Realty	South San Francisco	655,764	Q3 2021	100%
Alexandria District	Alexandria Real Estate Equities	San Carlos	526,178	Q2 2021	65%
201 Haskins Way	Alexandria Real Estate Equities	South San Francisco	315,000	Q2 2021	37%
The Shore at Sierra Point Phase II	Healthpeak Properties	Brisbane	270,404	Q4 2020	40%
1951 Harbor Bay Pky	SRM Ernst	Alameda	220,710	Q3 2022	100%
South Loop Center	SRM Ernst	Alameda	218,700	Q2 2021	58%

Developer spotlight

Lane Partners has over 7 million square feet of developments in the pipeline in the Bay Area with several key life science projects. Southline is a multi-building office and lab campus in South San Francisco that Lane Partners hopes they can fully lease up due to its prime location in South San Francisco, across the street from the San Bruno BART. Another one of Lane Partner's notable projects is called Berkeley Commons, located within Berkeley, California. The project will consist of two multi-story buildings to accommodate office, R&D, and lab tenants.



Top NIH - Funded institutions



Top vc-funded companies (2019)

Company	City	Equity Invested
BridgeBio	Palo Alto	\$299.2M
Maze Therapeutics	South San Francisco	\$191.0M
Perfect Day	Emeryville	\$174.8M
Grail	Menlo Park	\$125.0M
Nkarta	South San Francisco	\$114.0M
Encoded Therapeutics	South San Francisco	\$104.0M
IGM Biosciences	Mountain View	\$102.0M
Revolution Medicines	Redwood City	\$100.3M
Apollomics	Foster City	\$100.0M
Bolt Biotherapeutics	Redwood City	\$94.1M

Get more market information



San Mateo
Ava Jensen
Senior Research Analyst
ava.jensen@avisonyoung.com
408.913.6911

San Francisco
Patrick McKenzie
Research Analyst
patrick.mckenzie@avisonyoung.com
415.322.5056

Oakland | East Bay
Paul Magoria
Senior Research Analyst
paul.magoria@avisonyoung.com
510.254.4266

Silicon Valley | Northern California
Jennifer Vaux
U.S. Director of Office Research
jennifer.vaux@avisonyoung.com
408.913.6902